BioCentury | Jul 10, 2020
Product Development

Evive meets in Phase III for chemotherapy-induced neutropenia; plus regulatory updates for Biogen, Eisai, Merck, AZ

...Evive planning BLA, MAA for neutropenia therapy following pivotal trial readout Evive Biotech Inc. said efbemalenograstim alfa met...
...Assistant Editor Benegrastim (F-627) aducanumab (BIIB037) Keytruda, pembrolizumab (MK-3475, lambrolizumab) Lenvima/Keytruda, lenvatinib mesylate/pembrolizumab Brilinta, Brilique, ticagrelor (AZD6140, Possia) Biogen Inc. Eisai Co. Ltd. Evive Biotech Inc. Poly(ADP-ribose...
BioCentury | Feb 2, 2018
Clinical News

Generon's benegrastim meets in Phase III for CIN

...Inc. (NASDAQ:AMGN). Benegrastim is a long-acting recombinant fusion protein containing human G-CSF and human IgG2-Fc. Generon (Shanghai)...
...use of antibiotic and pain medications and electrocardiogram endpoints Status: Phase III data Milestone: NA Chris Lieu benegrastim F-627 Evive Biotech Inc. Granulocyte...
BioCentury | Nov 3, 2016
Translation in Brief

The I’s have it

...fusion protein RG7880 (UTTR1147A) in Phase I for ulcerative colitis and diabetic foot ulcers, and Generon (Shanghai)...
BioCentury | Dec 11, 2014
Distillery Therapeutics

Indication: Infectious disease

...protein iboctadekin (SB-485232) in Phase I testing to treat ovarian cancer and non-Hodgkin's lymphoma (NHL). Generon (Shanghai)...
BioCentury | Sep 4, 2014
Distillery Therapeutics

Indication: Endocrine/metabolic disease

...inflammation and weight gain compared with control IgG. Next steps include studying additional IL-22-mediated effects. Generon (Shanghai)...
BioCentury | Mar 20, 2014
Distillery Therapeutics

Indication: Autoimmune disease

...could include testing the topical application of small molecule PIM1 inhibitors in patients with psoriasis. Generon (Shanghai)...
BioCentury | Sep 10, 2012
Clinical News

F-652: Phase I started

...2, 8, 30, 120 and 250 µg/kg subcutaneous F-652 in about 40 healthy male volunteers. Generon (Shanghai)...
BioCentury | May 14, 2012
Clinical News

F-627: Phase II started

...200 breast cancer patients receiving myelotoxic chemotherapy. Amgen Inc. (NASDAQ:AMGN, Thousand Oaks, Calif.) markets Neulasta. Generon (Shanghai)...
Items per page:
1 - 8 of 8
BioCentury | Jul 10, 2020
Product Development

Evive meets in Phase III for chemotherapy-induced neutropenia; plus regulatory updates for Biogen, Eisai, Merck, AZ

...Evive planning BLA, MAA for neutropenia therapy following pivotal trial readout Evive Biotech Inc. said efbemalenograstim alfa met...
...Assistant Editor Benegrastim (F-627) aducanumab (BIIB037) Keytruda, pembrolizumab (MK-3475, lambrolizumab) Lenvima/Keytruda, lenvatinib mesylate/pembrolizumab Brilinta, Brilique, ticagrelor (AZD6140, Possia) Biogen Inc. Eisai Co. Ltd. Evive Biotech Inc. Poly(ADP-ribose...
BioCentury | Feb 2, 2018
Clinical News

Generon's benegrastim meets in Phase III for CIN

...Inc. (NASDAQ:AMGN). Benegrastim is a long-acting recombinant fusion protein containing human G-CSF and human IgG2-Fc. Generon (Shanghai)...
...use of antibiotic and pain medications and electrocardiogram endpoints Status: Phase III data Milestone: NA Chris Lieu benegrastim F-627 Evive Biotech Inc. Granulocyte...
BioCentury | Nov 3, 2016
Translation in Brief

The I’s have it

...fusion protein RG7880 (UTTR1147A) in Phase I for ulcerative colitis and diabetic foot ulcers, and Generon (Shanghai)...
BioCentury | Dec 11, 2014
Distillery Therapeutics

Indication: Infectious disease

...protein iboctadekin (SB-485232) in Phase I testing to treat ovarian cancer and non-Hodgkin's lymphoma (NHL). Generon (Shanghai)...
BioCentury | Sep 4, 2014
Distillery Therapeutics

Indication: Endocrine/metabolic disease

...inflammation and weight gain compared with control IgG. Next steps include studying additional IL-22-mediated effects. Generon (Shanghai)...
BioCentury | Mar 20, 2014
Distillery Therapeutics

Indication: Autoimmune disease

...could include testing the topical application of small molecule PIM1 inhibitors in patients with psoriasis. Generon (Shanghai)...
BioCentury | Sep 10, 2012
Clinical News

F-652: Phase I started

...2, 8, 30, 120 and 250 µg/kg subcutaneous F-652 in about 40 healthy male volunteers. Generon (Shanghai)...
BioCentury | May 14, 2012
Clinical News

F-627: Phase II started

...200 breast cancer patients receiving myelotoxic chemotherapy. Amgen Inc. (NASDAQ:AMGN, Thousand Oaks, Calif.) markets Neulasta. Generon (Shanghai)...
Items per page:
1 - 8 of 8